Ultragenyx Pharmaceutical Inc. (RARE) stock
Close on Nov 13, 2026Market cap $1.59BP/E –Yield –
Ultragenyx Pharmaceutical Inc. grew revenue 15.8% to $730.00M over the twelve months to Sep 30, 2026. Free cash flow was -$442.00M. At the latest close the market valued the company at $1.59B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.59B
- P/E ratio
- –
- Price to sales
- 2.17
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -27.88%
Fundamentals
- Revenue
- $730.00M
- Net income
- -$524.00M
- EPS, diluted
- -$5.19
- Free cash flow
- -$442.00M
- Book value per share
- -$3.68
- Diluted shares
- 102M
Trading
- Next earnings
- Feb 11, 2027 (estimated, after the close)
- Previous close
- $16.27
- Open
- $16.30
- Day's range
- $15.85 – $16.32
- Volume
- 1,679,426
- Average volume (20 days)
- 3,527,871
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $12.73 – $39.89
- RSI (14 days)
- 49.1
- Volatility (1 year)
- 82.3%
- Relative volume
- 0.45×
- WACC
- 10.5%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RARE | S&P 500 | Difference | RARE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.8% | -3.0% | +10.8 pts | ||
| 3 months | -39.0% | -2.8% | −36.3 pts | ||
| Year to date | -30.1% | +11.5% | −41.6 pts | ||
| 1 year | -51.1% | +13.5% | −64.6 pts | ||
| 3 years | -54.5% | +77.7% | −132.2 pts | -23.1% | +21.1% |
| 5 years | -80.0% | +72.6% | −152.6 pts | -27.5% | +11.5% |
| 10 years | -80.4% | +308.2% | −388.6 pts | -15.0% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ultragenyx Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Ultragenyx Pharmaceutical
Pharmaceutical Preparations
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company engaged in the identification, acquisition, development, and commercialization of therapeutic products. Its business centers on treatments for serious medical conditions, with commercial products and collaborations that include therapies such as Crysvita, Dojolvi, Mepsevii, and Evkeeza. The organization collaborates with biopharmaceutical partners and institutions to advance research, clinical development, licensing arrangements, and product distribution.
Company profile, executives and historyUltragenyx Pharmaceutical stock: common questions
What is Ultragenyx Pharmaceutical's stock price?
RARE closed at $16.08 on Nov 13, 2026, down 1.17% on the day. Over the past 52 weeks it traded between $12.73 and $39.89.
What is Ultragenyx Pharmaceutical's market cap?
Ultragenyx Pharmaceutical was worth $1.59B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is RARE's P/E ratio?
Ultragenyx Pharmaceutical lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.19), so it has no meaningful P/E ratio.
How much revenue does Ultragenyx Pharmaceutical make?
Ultragenyx Pharmaceutical reported revenue of $730.00M for the twelve months to Sep 30, 2026, up 15.8% from a year earlier.
Does Ultragenyx Pharmaceutical pay a dividend?
No. Ultragenyx Pharmaceutical has not paid a cash dividend over the last twelve months.
When does Ultragenyx Pharmaceutical report earnings next?
Ultragenyx Pharmaceutical is expected to report Q4 FY2026 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has RARE stock performed over the past year?
Including dividends, RARE returned -51.1% over the past year, against +13.5% for the S&P 500.
How many RARE shares are sold short?
24M shares were sold short at the latest FINRA report, 24.96% of the float, or 8.3 days of average trading volume.
Who are Ultragenyx Pharmaceutical's competitors?
Companies most similar to Ultragenyx Pharmaceutical by business, industry and size include MIRM, TVTX, AAPG, BBIO, PTCT.
See a number that looks wrong?